Therapeutic Peptides intermediate
Leuprolide Depot Formulation
Extended-release depot microsphere formulations of leuprolide providing 1-month to 12-month sustained testosterone suppression.
By Encyclopeptide Editorial | 1 min read
leuprolide depot microspheres PLGA prostate-cancer
Formulation Types
| Product | Dose | Duration | PLGA Ratio |
|---|---|---|---|
| Lupron Depot | 3.75 mg | 1 month | 75:25 |
| Lupron Depot | 11.25 mg | 3 months | 75:25 |
| Eligard | 7.5 mg | 1 month | 50:50 |
| Eligard | 22.5 mg | 3 months | 50:50 |
| Eligard | 45 mg | 12 months | 50:50 |
Formulation Science
PLGA microspheres encapsulate leuprolide in a biodegradable matrix. Upon subcutaneous injection, PLGA slowly hydrolyzes, releasing leuprolide over the designated period.
Clinical Applications
Indicated for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
Chemical Identity
| Property | Value |
|---|---|
| Name | Leuprolide Depot Formulation |
| Category | Therapeutic Peptides |
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Leuprolide Depot Formulation” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Leuprolide Depot Formulation with interactive quizzes on Wikipept.
Take a Quiz on Wikipept